135 related articles for article (PubMed ID: 34919339)
1. Neoadjuvant chemotherapy alters peripheral and tumour-infiltrating immune cells in breast cancer revealed by single-cell RNA sequencing.
Zhou H; Li G; Yin J; Wang T; Hu H; Li T; Zhou Q; Hu J; Wang L; Dong S; Wei C; Zhang C; Lu Y; Zhou W; Huang C; Yang H; Zhou D; Wang L; Wu K
Clin Transl Med; 2021 Dec; 11(12):e621. PubMed ID: 34919339
[No Abstract] [Full Text] [Related]
2. Protocol for Single-Cell Analysis of Tumor-Infiltrating B Cells Isolated from Human Breast Cancer Tissue Before and After Neo-adjuvant Chemotherapy.
Lu Y; Liao JY; Su S
STAR Protoc; 2020 Jun; 1(1):100040. PubMed ID: 33111088
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
4. The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type.
Miskad UA; Rifai RA; Masadah R; Nelwan B; Ahmad D; Cangara H; Prihantono P; Zainuddin AA; Rahawarin H
Breast Dis; 2021; 40(S1):S9-S14. PubMed ID: 34092582
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
De Angelis C; Nagi C; Hoyt CC; Liu L; Roman K; Wang C; Zheng Y; Veeraraghavan J; Sethunath V; Nuciforo P; Wang T; Tsimelzon A; Mao S; Hilsenbeck SG; Trivedi MV; Cataldo ML; Pavlick A; Wolff AC; Weigelt B; Reis-Filho JS; Prat A; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
Clin Cancer Res; 2020 Feb; 26(3):738-745. PubMed ID: 31653641
[TBL] [Abstract][Full Text] [Related]
6. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
[TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
Kochi M; Iwamoto T; Niikura N; Bianchini G; Masuda S; Mizoo T; Nogami T; Shien T; Motoki T; Taira N; Tokuda Y; Doihara H; Matsuoka J; Fujiwara T
Breast Cancer Res Treat; 2018 Jan; 167(1):39-47. PubMed ID: 28905250
[TBL] [Abstract][Full Text] [Related]
8. Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1
Liang H; Li H; Xie Z; Jin T; Chen Y; Lv Z; Tan X; Li J; Han G; He W; Qiu N; Jiang M; Zhou J; Xia H; Zhan Y; Cui L; Guo W; Huang J; Zhang X; Wu YL
Thorac Cancer; 2020 Oct; 11(10):2941-2954. PubMed ID: 32894006
[TBL] [Abstract][Full Text] [Related]
9. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
Ladoire S; Mignot G; Dabakuyo S; Arnould L; Apetoh L; Rébé C; Coudert B; Martin F; Bizollon MH; Vanoli A; Coutant C; Fumoleau P; Bonnetain F; Ghiringhelli F
J Pathol; 2011 Jul; 224(3):389-400. PubMed ID: 21437909
[TBL] [Abstract][Full Text] [Related]
10. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
Skriver SK; Jensen MB; Knoop AS; Ejlertsen B; Laenkholm AV
Breast Cancer Res; 2020 May; 22(1):46. PubMed ID: 32410705
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy.
Sakaguchi A; Horimoto Y; Onagi H; Ikarashi D; Nakayama T; Nakatsura T; Shimizu H; Kojima K; Yao T; Matsumoto T; Ogura K; Kitano S
Breast Cancer Res; 2021 Oct; 23(1):99. PubMed ID: 34715905
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.
Park YH; Lal S; Lee JE; Choi YL; Wen J; Ram S; Ding Y; Lee SH; Powell E; Lee SK; Yu JH; Ching KA; Nam JY; Kim SW; Nam SJ; Kim JY; Cho SY; Park S; Kim J; Hwang S; Kim YJ; Bonato V; Fernandez D; Deng S; Wang S; Shin H; Kang ES; Park WY; Rejto PA; Bienkowska J; Kan Z
Nat Commun; 2020 Dec; 11(1):6175. PubMed ID: 33268821
[TBL] [Abstract][Full Text] [Related]
16. Expression of epithelial-mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer.
Lee KH; Kim EY; Park YL; Do SI; Chae SW; Park CH
Tumour Biol; 2017 Jun; 39(6):1010428317710575. PubMed ID: 28621227
[TBL] [Abstract][Full Text] [Related]
17. The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting.
Badr NM; Berditchevski F; Shaaban AM
Pathobiology; 2020; 87(2):61-74. PubMed ID: 31715606
[TBL] [Abstract][Full Text] [Related]
18. Relevance of tumor-infiltrating lymphocytes in breast cancer.
Dushyanthen S; Beavis PA; Savas P; Teo ZL; Zhou C; Mansour M; Darcy PK; Loi S
BMC Med; 2015 Aug; 13():202. PubMed ID: 26300242
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
20. Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC.
Kaewkangsadan V; Verma C; Eremin JM; Cowley G; Ilyas M; Eremin O
BMC Cancer; 2018 Feb; 18(1):123. PubMed ID: 29390966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
